- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11:26 | March Bio's MB-105 gains FDA RMAT for CD5+ T-cell lymphoma | ||
| Di | Novartis opens California site for RLT manufacturing | ||
| Mo | SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases | ||
| Fr | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | ||
| Do | Leukogene Therapeutics gains FDA ODD status for M2T-CD33 | ||
| 05.11. | AmacaThera and Pacira sign agreement for AMT-143 | ||
| 04.11. | CNX Therapeutics expands CNS portfolio with Sativex acquisition | ||
| 03.11. | Calluna secures FDA orphan drug designation for CAL101 in IPF | ||
| 31.10. | Arcutis introduces roflumilast cream for paediatric atopic dermatitis | ||
| 30.10. | Samsung Bioepis to acquire commercial rights for Byooviz in Europe | ||
| 29.10. | Myrio Therapeutics announces partnership for immunotherapy development | ||
| 28.10. | Hovione finalises $100m investment for East Windsor site expansion in US | ||
| 27.10. | Biogen acquires global rights to Vanqua C5aR1 antagonist | ||
| 24.10. | Naobios and TMIMS to develop new live mpox vaccine | ||
| 23.10. | Boehringer's Jascayd gains NMPA approval for idiopathic pulmonary fibrosis | ||
| 22.10. | Portal Therapeutics receives FDA orphan, fast track designations for PORT-77 | ||
| 21.10. | Citius Oncology finalises McKesson deal for Lymphir distribution | ||
| 17.10. | Tempus partners with Whitehawk on oncology research | ||
| 16.10. | FDA accepts Chiesi triple combination inhaler application for asthma | ||
| 15.10. | iQure, University of Padova collaborate to investigate iQ-007 mechanism | ||
| 14.10. | US FDA grants BeOne's sonrotoclax breakthrough designation for MCL | ||
| 13.10. | Adcendo receives FDA fast track status for ADCE-D01 to treat STS | ||
| 10.10. | Bio-Thera, Intas extend partnership for golimumab biosimilar | ||
| 09.10. | Nilo Therapeutics raises $101m to develop neural circuit therapies | ||
| 08.10. | AeroRx secures $21m for nebulised COPD treatment development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .